Olema Pharmaceuticals, Inc.
OLMA
$4.26
$0.051.19%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -19.39% | 13.01% | 22.40% | -22.85% | -1.61% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.69% | 61.17% | 55.22% | 28.12% | 22.03% |
| Operating Income | -10.69% | -61.17% | -55.22% | -28.12% | -22.03% |
| Income Before Tax | -25.38% | -60.71% | -51.19% | -9.49% | -2.27% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -25.38% | -60.71% | -51.19% | -9.49% | -2.27% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -25.38% | -60.71% | -51.19% | -9.49% | -2.27% |
| EBIT | -10.69% | -61.17% | -55.22% | -28.12% | -22.03% |
| EBITDA | -10.64% | -61.39% | -55.50% | -28.27% | -22.14% |
| EPS Basic | -4.40% | -26.21% | -9.38% | 20.49% | 24.98% |
| Normalized Basic EPS | 5.48% | -26.24% | -9.40% | 11.76% | 17.12% |
| EPS Diluted | -4.40% | -26.21% | -9.38% | 20.49% | 24.98% |
| Normalized Diluted EPS | 5.48% | -26.24% | -9.40% | 11.76% | 17.12% |
| Average Basic Shares Outstanding | 20.10% | 27.32% | 38.22% | 37.72% | 36.32% |
| Average Diluted Shares Outstanding | 20.10% | 27.32% | 38.22% | 37.72% | 36.32% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |